| Bim is a suppressor of Myc-induced mouse B cell leukemia A Egle, AW Harris, P Bouillet, S Cory Proceedings of the National Academy of Sciences 101 (16), 6164-6169, 2004 | 631 | 2004 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 376 | 2022 |
| p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa LJ Valente, DHD Gray, EM Michalak, J Pinon-Hofbauer, A Egle, CL Scott, ... Cell reports 3 (5), 1339-1345, 2013 | 327 | 2013 |
| A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European … AC Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, ... Leukemia 30 (4), 929-936, 2016 | 275 | 2016 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 273 | 2022 |
| VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia A Egle, AW Harris, ML Bath, L O'Reilly, S Cory Blood 103 (6), 2276-2283, 2004 | 251 | 2004 |
| Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia … A Villunger, A Egle, M Kos, BL Hartmann, S Geley, R Kofler, R Greil Cancer research 57 (16), 3331-3334, 1997 | 207 | 1997 |
| Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo G Lutzny, T Kocher, M Schmidt-Supprian, M Rudelius, L Klein-Hitpass, ... Cancer cell 23 (1), 77-92, 2013 | 200 | 2013 |
| Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera H Gisslinger, O Zagrijtschuk, V Buxhofer-Ausch, J Thaler, E Schloegl, ... Blood, The Journal of the American Society of Hematology 126 (15), 1762-1769, 2015 | 199 | 2015 |
| Molecular and cellular mechanisms of CLL: novel therapeutic approaches L Pleyer, A Egle, TN Hartmann, R Greil Nature reviews Clinical oncology 6 (7), 405-418, 2009 | 182 | 2009 |
| Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma I Tinhofer, I Marschitz, T Henn, A Egle, R Greil Blood, The Journal of the American Society of Hematology 95 (2), 610-618, 2000 | 176 | 2000 |
| Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance A Villunger, A Egle, I Marschitz, M Kos, G Böck, H Ludwig, S Geley, ... Blood, The Journal of the American Society of Hematology 90 (1), 12-20, 1997 | 164 | 1997 |
| Bim and Bmf in tissue homeostasis and malignant disease JD Pinon, V Labi, A Egle, A Villunger Oncogene 27 (1), S41-S52, 2008 | 154 | 2008 |
| Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo BS Hanna, F McClanahan, H Yazdanparast, N Zaborsky, V Kalter, ... Leukemia 30 (3), 570-579, 2016 | 149 | 2016 |
| Differential Sensitivity of CD4+ and CD8+T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia I Tinhofer, I Marschitz, M Kos, T Henn, A Egle, A Villunger, R Greil Blood, The Journal of the American Society of Hematology 91 (11), 4273-4281, 1998 | 145 | 1998 |
| microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia D Asslaber, JD Piñón, I Seyfried, P Desch, M Stöcher, I Tinhofer, A Egle, ... Blood, The Journal of the American Society of Hematology 115 (21), 4191-4197, 2010 | 144 | 2010 |
| Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL JP Hofbauer, C Heyder, U Denk, T Kocher, C Holler, D Trapin, D Asslaber, ... Leukemia 25 (9), 1452-1458, 2011 | 122 | 2011 |
| Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation V Labi, M Erlacher, G Krumschnabel, C Manzl, A Tzankov, J Pinon, A Egle, ... Genes & development 24 (15), 1602-1607, 2010 | 120 | 2010 |
| PKCβ is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCβ as a therapeutic target in chronic lymphocytic leukemia C Holler, JD Piñón, U Denk, C Heyder, S Hofbauer, R Greil, A Egle Blood, The Journal of the American Society of Hematology 113 (12), 2791-2794, 2009 | 96 | 2009 |
| A modified scoring of the NCCN‐IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin T Melchardt, K Troppan, L Weiss, C Hufnagl, D Neureiter, ... British journal of haematology 168 (2), 239-245, 2015 | 93 | 2015 |
